Jounce Therapeutics Enters Into Agreement to Be Acquired by Concentra Biosciences for $1.85 in Cash per Share Plus Contingent Value Rights March 31, 2023
BioNTech and OncoC4 Announce Strategic Collaboration to Co-Develop and Commercialize Novel Checkpoint Antibody in Multiple Solid Tumor Indications March 31, 2023
Prelude Therapeutics Announces Clinical Trial Collaboration with BeiGene to Evaluate PRT2527 in Combination with Zanubrutinib in Hematologic Cancers March 31, 2023
Leap Therapeutics Provides Update on BeiGene Option Agreement for DKN-01; DisTinGuish Trial of DKN-01 + tislelizumab & chemo to continue as a clinical collaboration March 31, 2023
Merck Strengthens Oncology Franchise by Securing Exclusive Worldwide Rights to Anti PD-L1 Antibody BAVENCIO® (avelumab) March 31, 2023
Open-Label Arm of Ph 2 KeyVibe-002 Trial of MK-7684A (Coformulation of Vibostolimab and Keytruda) to continue in Previously Treated mNSCLC Patients March 31, 2023
Ph 1b/2 Study initiated to Evaluate Pepinemab + Avelumab in 2L Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) patients March 31, 2023
Ph 1/2 clinical trials of GoCAR-T cell product candidates in combination with rimiducid in heavily pre-treated cancer patients discontinued March 31, 2023
First Patient dosed in FRIDA, a Ph Ib trial with iadademstat in R/R FLT3-mutant AML patients March 31, 2023
Ph 2/3 Trial for Eftilagimod Alpha plus Paclitaxel initiated in Metastatic Breast Cancer March 31, 2023
First Patient Dosed in the 300 mg Dose Group with Next Generation Chemotherapy-Capecitabine March 31, 2023
Results from INNATE Phase 2 Trial of JTX-8064 and Pimivalimab Demonstrate Deep and Durable Responses in Platinum Resistant Ovarian Cancer March 31, 2023
FAILED TRIAL: Ph 2 KeyVibe-002 Trial of MK-7684A (Vibostolimab + Pembrolizumab) in Previously Treated NSCLC patients did not meet primary PFS endpoint March 31, 2023
Pivotal Ph 3 INDIGO Trial of vorasidenib in IDH-Mutant Low-Grade Glioma Meets Primary Endpoint of PFS and Key Secondary Endpoint of Time to Next Intervention (TTNI) March 31, 2023
Dose Escalation Portion of Phase 1 Solid Tumors Trial of TRE-515 Produces Favorable Results in Heavily Pretreated Solid Tumor Patients March 31, 2023
Ph 3 Study Shows XTANDI® (enzalutamide) plus Leuprolide Significantly Improves Metastasis-Free Survival in Men with Non-Metastatic Prostate Cancer March 31, 2023
A First Complete Bone Marrow Response in a R/R AML Patient From The Very Low Dose Arm of Its AB8939 Ph 1/2 Clinical Trial (AB18001) reported March 31, 2023
KEYTRUDA + Chemo Significantly Improved PFS vs chemo Alone as 1L Therapy for Advanced or Recurrent Endometrial Carcinoma, Regardless of MMR Status March 31, 2023
Kisqali® Ph 3 NATALEE Trial Meets Primary Endpoint At Interim Analysis Demonstrating Clinically Meaningful Benefit In Patients With Early Breast Cancer March 31, 2023
